Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Notes Payables (2017 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Notes Payables for 11 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables changed 0.0% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 0.0% change, with the full-year FY2025 number at $1.2 million, changed 0.0% from a year prior.
  • Notes Payables was $1.2 million for Q4 2025 at Ekso Bionics Holdings, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $2.9 million in Q2 2023 to a low of $814000.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $1.2 million in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: plummeted 62.49% in 2021, then changed 0.0% in 2024.
  • Ekso Bionics Holdings' Notes Payables stood at $814000.0 in 2021, then skyrocketed by 183.78% to $2.3 million in 2022, then plummeted by 45.89% to $1.2 million in 2023, then changed by 0.0% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Notes Payables are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).